The company added that it remains committed to maintaining cGMP compliance and ensuring the supply of high-quality products to customers and patients worldwide.
NATCO Pharma, headquartered in Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.
The company’s consolidated net profit fell 23.5% to Rs 518.40 crore in Q2 FY26, compared with Rs 677.30 crore in Q2 FY25. Revenue from operations declined marginally to Rs 1,363 crore in Q2 FY26, compared with Rs 1,371.10 crore in Q2 FY25.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."